Dr. T. Shantha Raju (Raju) has more than 25 years of experience in the research and development of biotherapeutics, including mAbs, proteins, vaccines, gene therapy, and cell therapy. Raju contributed towards the successful development of Rituxan, Herceptin, Avastin, Xolair, Raptiva, Remicade, Stelara, Simponi, Darzalex, Infinzi, etc. at Genentech, Janssen, and Medimmune. Raju has published over 40 research papers, reviews articles and book chapters. He serves on the editorial boards of several leading journals. His book entitled “Co- and Post-Translational Modifications of Therapeutic Antibodies and Proteins” was recently published by Wiley. 

Dr. Raju obtained his Ph.D. in Bio-organic Chemistry from the University of Mysore, India and then completed Post-doctoral Fellowships at York University, Department of Chemistry, Toronto, Canada and Georgetown University Medical School, Washington, D.C. in the Department of Biochemistry.